Efficacy of Angiotensin Receptor Blockers (Valsartan, Candesartan, Losartan) in Lowering Blood Pressure: A Systematic Review

Shafa Shaomi Maharani, Dika Pramita Destiani

Abstract


Hypertension is a significant health issue that significantly increases the risk of cardiovascular disease. Angiotensin II receptor blockers (ARBs) are commonly used in Indonesia to treat hypertension, yet comprehensive comparative efficacy data within this drug class remain limited. This review seeks to evaluate the blood pressure-lowering efficacy of three particular angiotensin receptor blockers (ARBs)—Valsartan, Candesartan, and Losartan—in individuals diagnosed with hypertension. This systematic review identified randomized controlled trials (RCT) obtained from PubMed and Google Scholar using several keyword combinations. Among 20 RCTs with 6.425 patients treated with three ARBs, all included studies demonstrated significant blood pressure reductions. The mean reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP) were the greatest for Candesartan (-18.69/-10.25 mmHg), followed by Losartan (-14.80/-7.8 mmHg), and Valsartan (-8.94/-7.58 mmHg). Candesartan achieved the largest reduction, decreasing baseline systolic blood pressure (SBP)/diastolic blood pressure (DBP) by 38.16/18.95 mmHg over 12 weeks. In contrast, Valsartan showed the smallest reduction, with SBP decreasing by 0.81/0.04 mmHg after 66 months. It can also be linked to the pharmacokinetic properties of the drugs, where Valsartan has a higher bioavailability, and Losartan has a lower bioavailability compared to the other ARBs. It can be concluded that ARBs, including Valsartan, Candesartan, and Losartan, are generally effective in reducing blood pressure in hypertensive patients, with Candesartan showing the greatest efficacy. Future research should involve direct comparative trials of Valsartan, Candesartan, and Losartan, along with studies on their molecular mechanisms, to increase effective hypertension treatments.

Keywords


Angiotensin Receptor Blocker; Blood Pressure; Hypertension; Systematic Review

Full Text:

PDF

References


Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104.

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. The Lancet. 2005;365(9455):217-223.

World Health Organization. World Health Statistics 2015.; 2015.

Kementerian Kesehatan RI. Hasil Riset Kesehatan Dasar Tahun 2018.; 2018.

Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control. Circulation. 2016;134(6):441-450.

Katsanos AH, Filippatou A, Manios E, et al. Blood Pressure Reduction and Secondary Stroke Prevention. Hypertension. 2017;69(1):171-179.

Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957-967.

James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA. 2014;311(5):507.

Omboni S, Volpe M. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan. Adv Ther. 2019;36(2):278-297.

Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.

Pradipta IS, Houtsma D, van Boven JFM, Alffenaar JWC, Hak E. Interventions to improve medication adherence in tuberculosis patients: a systematic review of randomized controlled studies. NPJ Prim Care Respir Med. 2020;30(1):21.

Ahn Y, Kim Y, Chang K, et al. A multicenter, randomized, and double-blind phase IV clinical trial to compare the efficacy and safety of fixed-dose combinations of amlodipine orotate/valsartan 5/160 mg versus valsartan/hydrochlorothiazide 160/12.5 mg in patients with essential hyperte. Medicine. 2018;97(37):e12329.

Serebruany VL, Pokov AN, Aradi D, et al. Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial. Am J Ther. 2014;21(6):482-490.

Na SH, Lee HY, Hong Baek S, et al. Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial. Clin Ther. 2015;37(8):1726-1739.

Shi R, Liu K, Shi D, Liu Q, Chen X. Effects of Amlodipine and Valsartan on Blood Pressure Variability and Pulse Wave Velocity in Hypertensive Patients. Am J Med Sci. 2017;353(1):6-11.

Park JB, Ha JW, Jung HO, Rhee MY. Randomized trial comparing the effects of a low-dose combination of nifedipine GITS and valsartan versus high-dose monotherapy on central hemodynamics in patients with inadequately controlled hypertension: FOCUS study. Blood Press Monit. 2014;19(5):294-301.

Giles TD, WMA, BJ, GAH, BDB, CW, & PM. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. The Lancet. 2014;383(9932).

Ruggenenti P, Trillini M, P Barlovic D, et al. Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. Diabetes Obes Metab. 2019;21(5):1177-1190.

Park JB, Shin JH, Kim DS, et al. Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension: the FOCUS Study. Clin Ther. 2016;38(4):832-842.

Wang KL, Yu WC, Lu TM, Chen LC, Leu HB, Chiang CE. Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial. J Chin Med Assoc. 2020;83(10):900-905.

Mancia G, Asmar R, Amodeo C, et al. Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. J Hypertens. 2015;33(2):401-411.

Ruggenenti P, Cortinovis M, Parvanova A, et al. Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. PLoS Med. 2021;18(7):e1003691.

Cho KI, Kim BH, Park YH, et al. Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study. Clin Ther. 2019;41(8):1508-1521.

Sohn IS, Kim CJ, Ahn T, et al. Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial. Clin Ther. 2017;39(8):1628-1638.

Hanna SM, Rabea HM, Abdelrahim MEA, Mahmoud HB. Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure. Hipertens Riesgo Vasc. 2024;41(1):17-25.

Tamuli S, KS, & DS. Comparative studies of efficacy and effect on oxidative stress of atenolol and candesartan in the hypertensive patients of North East India. International Journal of Pharma Sciences and Research. 2015;6(4).

Lai X, Dong Z, Wu S, et al. Efficacy and Safety of Chinese Herbal Medicine Compared With Losartan for Mild Essential Hypertension: A Randomized, Multicenter, Double-Blind, Noninferiority Trial. Circ Cardiovasc Qual Outcomes. 2022;15(3):e007923.

Scholtes RA, Mosterd CM, Hesp AC, Smits MM, Heerspink HJL, van Raalte DH. Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial. Diabetes Obes Metab. 2023;25(1):198-207.

Aftab RA, Khan AH, Adnan AS, Sulaiman SAS, Khan TM. Safety and Efficacy of Losartan 50 mg in Reducing Blood Pressure among Patients with Post-Dialysis Euvolemic Hypertension: A Randomized Control Trial. Sci Rep. 2017;7(1):17741.

Boonbaichaiyapruck S, Mekwiwatanawong W, Srisala K, Amnueypol M, Keesukphan P. Efficacy of Blood Pressure reduction of Losartan in selected Thai populations using Home Blood Pressure Monitoring and Office Blood Pressure measurements. ASEAN Heart Journal. 2015;23(1).

Mujeeb MMA, SAP, & JK. ). COMPARATIVE ANALYSIS OF EFFICACY AND SAFETY OF LOSARTAN, OLMESARTAN, TELMISARTAN AND VALSARTAN IN PATIENTS WITH HYPERTENSION. Journal of Evolution of Research in Medical Pharmacology. 2016;2(2):10-15.

Gallo G, Volpe M, Rubattu S. Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations. Vasc Health Risk Manag. 2022;18:507-515.

Abdullah A, Rusli MF. Pages: 58-64 To Cite This Article. Vol 11.; 2020.




DOI: https://doi.org/10.15416/pcpr.v10i2.59629

Refbacks

  • There are currently no refbacks.


                                                                         
Pharmacology and Clinical Pharmacy Research is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
 
                                                                      VIEW VISITOR STATS